GSK licenses Ionis' experimental hep B treatments in up to $262M deal
GSK $GSK may have walked away from two of Ionis’ $IONS antisense drugs (including the now-approved Tegsedi) in 2017 — but the British drugmaker held on as a partner to the biotechnology company’s experimental hepatitis B treatments.
On Tuesday, GSK exercised its option to license Ionis’ drugs — IONIS-HBVRx and IONIS-HBV-LRx — following positive mid-stage data. In return, Ionis receives up to $262 million in milestone payments, including a $25 million license fee. In addition, Ionis is also eligible to receive tiered royalties on net sales. Now, GSK is responsible for all development, regulatory and commercialization activities and costs for the two drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.